Our observation that GLP-1RAs may also reduce VTE among patients without obesity seems to suggest that there might be effects other than the weight loss driving the reduction in VTE. The findings still need to be validated in prospective studies, Chiang said
Why Did the FDA End Broad Compounding of Semaglutide and Tirzepatide
semaglutide for weight loss compared Key highlights Tirzepatide and semaglutide are once-weekly subcutaneous injectable medications approved for type 2 diabetes and chronic weight management in combination with a low-calorie diet and exercise
When your body isn't constantly fighting inflammatory fires and can efficiently complete its nightly repair work, the sleep architecture often improves
Hormonal changes can also make you feel hungrier or promote food cravings
Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazire JC, Chauffert B, et al